Compugen Ltd.
CGEN.TA
Tel Aviv Stock Exchange700.50
ILA
+0.80
- -
Compugen Ltd.
CGEN.TA
(Tel Aviv Stock Exchange)
Recent
price
700.50
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in the research, development, and commercialization of therapeutics and product candidates primarily in the fields of oncology and immunology. The company leverages a proprietary predictive computational discovery platform, Unigen™, to identify novel drug targets, focusing mainly on immune checkpoint and myeloid protein target candidates. Its product pipeline encompasses early and preclinical-stage immuno-oncology programs designed to develop cancer immunotherapy drugs that can function as monotherapy or in combination with other treatments, addressing unmet medical needs across various cancer types and patient populations. Additionally, Compugen is developing a preclinical-stage fusion protein candidate for autoimmune diseases. The company operates globally with active focus on markets including the United States and Europe. Founded in 1993, Compugen is headquartered in Holon, Israel. Recent major developments include a significant collaboration and exclusive license agreement with Gilead Sciences for a preclinical antibody program targeting IL-18 binding protein. Under this agreement, Compugen manages ongoing preclinical development and a Phase I study for the drug candidate COM-503, with Gilead holding exclusive rights for later-stage development and commercialization. The deal includes an upfront payment of $60 million to Compugen, a $30 million milestone upon IND clearance, and potential development, regulatory, and commercial milestone payments totaling up to $848 million. Compugen also maintains a clinical-stage partnered program with AstraZeneca involving the PD-1/TIGIT bispecific antibody rilvegostomig (previously AZD2936), which is in Phase 3 development. Furthermore, Compugen expanded its strategic collaboration with Bristol Myers Squibb, supported by a $20 million investment to enhance clinical execution. These partnerships underscore Compugen’s strategic shift towards collaborative development of immuno-oncology drug candidates utilizing its computational discovery technology. Compugen directly engages in the research, development, and commercialization of its therapeutic candidates across oncology and immunology, supported by its discovery capabilities and computational biology platform. The company’s strategy focuses on generating novel cancer immunotherapy solutions with significant potential in both monotherapy and combination treatment settings. With a workforce of approximately 74 employees, Compugen continues to advance its pipeline through a combination of internal programs and external partnerships, aiming to deliver innovative medical solutions and expand its global market footprint. The headquarters remain in Holon, Israel.